SUMMARY
Humalog® Mix75/25™ [75% insulin lispro protamine suspension and 25% insulin lispro injection, (rDNA origin)] is a mixture of insulin lispro solution, a rapid-acting blood glucose-lowering agent and insulin lispro protamine suspension, an intermediate-acting blood glucose-lowering agent.
Humalog Mix75/25, a mixture of 75% insulin lispro protamine suspension and 25% insulin lispro, is indicated in the treatment of patients with diabetes mellitus for the control of hyperglycemia. Humalog Mix75/25 has a more rapid onset of glucose-lowering activity compared to Humulin 70/30 while having a similar duration of action. This profile is achieved by combining the rapid onset of Humalog with the intermediate action of insulin lispro protamine suspension.
|
NEWS HIGHLIGHTS
Published Studies Related to Humalog Mix75 / 25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection)
The impact of the timing of Humalog Mix25 injections on blood glucose fluctuations in the postprandial period in elderly patients with type 2 diabetes. [2005.12]
CONCLUSIONS: Mix25 improves postprandial BG and yields a greater effect on BG excursions compared with monotherapy with glibenclamide. The timing of Mix25 did not impact the level of BG or BG fluctuations after meals, which may be important for individuals with changing dietary pattern.
Randomized, multinational, open-label, 2-period, crossover comparison of biphasic insulin aspart 30 and biphasic insulin lispro 25 and pen devices in adult patients with type 2 diabetes mellitus. [2004.04]
OBJECTIVE: The goal of this study was to compare the efficacy and safety profiles of biphasic insulin aspart 30 (30% soluble insulin aspart and 70% protaminated insulin aspart [BIAsp 30]) and biphasic insulin lispro 25 (25% soluble insulin lispro and 75% neutral protamine lispro [Mix25]) used in a BID injection regimen in patients with type 2 diabetes mellitus (DM). Also assessed was patients' preference for pen device--the NovoMix 30 FlexPen /NovoLog Mix 70/30 FlexPen (FlexPen) versus the Humalog Mix25 Pen/Humalog Mix75/25 Pen (Humalog Pen)... CONCLUSIONS: In this study, glycemic control with BIAsp 30 and Mix25 was found to be comparable in these patients with type 2 DM. Safety profiles were similar for both regimens. Patients preferred and experienced fewer problems with the FlexPen than the Humalog Pen.
Humalog Mix50 before carbohydrate-rich meals in type 2 diabetes mellitus. [2003.09]
CONCLUSIONS: Compared with treatment with Mix25 twice daily, treatment with Mix50 before breakfast and Mix25 before the evening meal resulted in better pp glycaemic control following a carbohydrate-rich meal, and similar fasting BG, A1C and incidence of hypoglycaemia in patients with type 2 diabetes.
Humalog Mix25 improves 24-hour plasma glucose profiles compared with the human insulin mixture 30/70 in patients with type 2 diabetes mellitus. [2003.03]
OBJECTIVE: To compare the effects of Humalog Mix25 (Humalog Mix75/25 in the USA) (Mix25) and human insulin 30/70 (30/70) on the 24-hour inpatient plasma glucose (PG) profile in patients with type 2 diabetes mellitus (T2DM)... CONCLUSION: In patients with T2DM, Mix25 improved the 24-hour PG profile with lower postprandial PG excursions than with human insulin 30/70.
Comparative efficacy of preprandial or postprandial Humalog Mix75/25 versus glyburide in patients 60 to 80 years of age with type 2 diabetes mellitus. [2002.01]
BACKGROUND: Humalog Mix75/25 (Mix75/25) is a novel premixed insulin containing 75% neutral protamine lispro (an intermediate-acting insulin) and 25% insulin lispro. OBJECTIVE: The purpose of this study was to compare glycemic control and hypoglycemia rates with Mix75/25 versus glyburide, and with preprandial versus postprandial Mix75/25, in patients aged 60 to 80 years with type 2 diabetes mellitus and persistent hyperglycemia on sulfonylurea therapy... CONCLUSIONS: Compared with glyburide, Mix75/25 significantly improved glycemic control in older patients with type 2 diabetes mellitus, could be administered after meals without compromising glycemic control, and was well tolerated.
Clinical Trials Related to Humalog Mix75 / 25 (Insulin Lispro Protamine Suspension / Insulin Lispro Injection)
Comparison of Insulins Aspart and Lispro in Insulin Pumps [Active, not recruiting]
The purpose of the study is to study compare the glycemic control between insulins aspart and
lispro 48 to 100 hours after pump infusion line change in subjects with type 1 using diabetes
using an insulin pump.
Lispro Mix 25 vs. Glargine in Type 2 Diabetics [Completed]
In patients with type 2 diabetes who have not been on insulin therapy before the study will
achieve better glycemic control by the treatment regiment consisting of two times daily
insulin lispro mix 25 than by the treatment regiment with consisting of one time daily
injection of insulin glargine. Improved glycemic control will be compared by the fasting
plasma glucose and blood glucose excursions 2 hours after breakfast.
Local Registration Trial in China Humalog Mix 50 [Completed]
The primary objective of this study is to compare the 2-hour PPBG excursion following a
standard test meal in insulin-requiring diabetic patients treated twice daily with human
insulin mix 50/50, versus the 2-hour PPBG excursion in patients treated twice daily with
insulin lispro mix 50/50.
Lyspro Insulin vs Regular Insulin in Cirrhotic Patients [Completed]
OBJECTIVE: To compare lispro insulin and regular insulin in the glycemic control of patients
with liver cirrhosis and type 2 diabetes subjects. METHODS: 108 patients with liver
cirrhosis and type 2 diabetes were randomly treated with regular insulin or lispro. After
122 weeks a cross-over was carried out and patients followed-up for 122 weeks. Then, all
patients received a standard breakfast of 145 kcal following 12 U. I. of regular insulin or
lispro, and C-peptide and insulin serum levels were determined over 300 minutes.
Phase II PK Study With Humalog and Humulin R With and Without rHuPH20 in T1DM [Recruiting]
Humalog and Humulin R are FDA approved medications for the treatment of diabetes mellitus.
Recombinant human hyaluronidase (rHuPH20) is approved by the FDA as an aid to the absorption
and dispersion of other injectable drugs. In this study, rHuPH20 will be co-administered with
both Humalog and Humulin R in order to determine if it improves the absorption of these
insulins to more closely mimic the body's natural increase in insulin in response to a meal.
|
